特利加压素治疗失代偿期乙型肝炎肝硬化患者消退腹水的作用及对肝肾功能的影响

doi:10.3969/j.issn.1672-5069.2016.06.012

Abstract

Abstract: Objiective To explore the therapeutic effect of telipressin in treatment of patients with decompensated cirrhosis resulting from chronic hepatitis B. Methods 50 patients with decompensated cirrhosis resulting from chronic hepatitis B were admitted to Anhui Provincial Hospital between August 2014 and June 2016. The patients were divided into telipressin treatment group（n=25） and traditional treatment group（n=25） accordng to the different treatment approaches. The urine volume，abdominal perimeter，and the serum levels of alanine aminotransferase（ALT），AST，total bilirubin，alkaline phosphatase（ALP），creatinine， urea nitrogen on day 1，3，7 after treatment were compared between the two groups. Results On day 3 and 7 after treatment，serum levels creatinine in telipressin treatment group were（100.88±28.51） μmol/L and （95.28±25.34） μmol/L，respectively，significantly lower than those in traditional treatment group [（124.34±19.88）μmol/L and （113.99±26.89） μmol/L，P＜0.05]；serum levels of urea nitrogen in telipressin treatment group were （10.13±4.76） μmol/L and（9.05±4.53） μmol/L，respectively，markedly lower than those in traditional treatment group[（13.12±5.28）μmol/L and （12.34±5.99） μmol/L，P＜0.05]；urine volumes in telipressin treatment group were （1825.6±613.34） ml and （1990.8±731.16） ml，respectively，much greater than those in traditional treatment group[（1334.42±542.33）ml and（1421.54±698.99） ml，P＜0.05]；abdominal perimeters in telipressin treatment group were（91.32±7.4） cm and（91.04±7.45） cm， respectively，smaller than those in traditional treatment group [（96.28±6.89）cm and （96.55±7.99） cm，P＜0.05]；after seven day treatment，ascites subsided in 76.0% in telipressin treatment group （19/25），much higher than 40.0% in patients in traditional treatment group（10/25，P＜0.05）；However，serum levels of ALT，AST，ALP，total bilirubin on day 3 and 7 after treatment were not significantly different between the two groups（P＞0.05）. Conclusion Terlipressin is effective for patients with decompensated cirrhosis resulting from chronic hepatitis B. The treatment can improve renal functions and decrease ascites.

Key words: Decompensated cirrhosis, Terlipressin, Hepatic and renal function, Ascites.

Cheng Ya，Qiao Xiaofei，Jia Weidong.. Therapeutic effects of terlipressin in treatment of patients with decompensated cirrhosis resulting from chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 687-691.

References

[1] Samuel D，Muller R，Alexander G，et al. Liver transplantation in European patients with the hepatitis B surface antigen. New Engl J Med，1993，329（25）:1842-1847.
[2] Ginés P，Quintero E，Arroyo V，et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology，1987，7（1）:122-128.
[3] Planas R，Montoliu S，Balleste B，et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol，2006，4（11）:1385-1394.
[4] Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012．Hepatology，2013，57（4）:1651-1653．
[5] Angeli P，Fasolato S，Mazza E，et al. Combined versus sequential diuretic treatment of ascites in nonazotemic patients with cirrhosis:results of an open randomized clinical trial. Gut，2010，59（1）:98-104.
[6] Bernardi M. Optimum use of diuretics in managing ascites in patients with cirrhosis. Gut，2010，59（1）:10-11.
[7] Chan CC，Lee FY，Wang SS，et al. Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats:Role of nitric oxide and prostaglandin. Hepatology，1999，30（3）:630-635.
[8] 王天才，张国. 特利加压素、垂体后叶素对正常及门脉高压兔门脉血流动力学影响的研究. 中华消化杂志，2002，22（10）:595-597.
[9] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志，2011，14（2）：81-89.
[10] Ginès P，Schrier RW. Renal failure in cirrhosis. New Engl J Med，2010，362（1）:1279-1290.
[11] Sort P，Navasa M，Arroyo V，et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med，1999，341（6）:403-409.
[12] Shear L，Ching S，Gabuzda GJ. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. New Engl J Med，1970，282（25）:1391-1396.
[13] Kiszka-Kanowitz M. Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scan J Gastroenterol，2004，39（5）:486-492.
[14] Gines P，Guevara M，Arroyo V，et al. Hepatorenal syndrome. Lancet，2003，362（9398）:1819-1827.
[15] Sanyal AJ，Boyer T，Garcia-Tsao G，et al. A randomized，prospective，double-blind，placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology，2008，134（5）:1360-1368.
[16] Moreau R，Lebrec D. The use of vasoconstrictors in patients with cirrhosis:Type 1 HRS and beyond. Hepatology，2006，43（3）:385-394.
[17] Fimiani B，Guardia DD，Puoti C，et al. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function:A multicentric study. Eur J Intern Med，2011，22（6）:587-590.
[18] Angeli P，Lenz K，Ginès P，et al. EASL clinical practice guidelines on the management of ascites，spontaneous bacterial peritonitis，and hepatorenal syndrome in cirrhosis. J Hepatol，2010，53（3）:397-417.
[19] Salerno F，Guevara M，Bernardi M，et al. Refractory ascites: pathogenesis，definition and therapy of a severe complication in patients with cirrhosis. Liver Int，2010，30（7）:937-947.
[20] Salman TA，Edrees AM，El-Said HH，et al. Effect of different therapeutic modalities on systemic，renal，and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol，2016，28（7）:777-785.
[21] Fayed N，Refaat EK，Yassein TE，et al. Effect of perioperative terlipressin infusion on systemic，hepatic，and renal hemodynamics during living donor liver transplantation. J Crit Care，2013，28（5）:775-782.
[22] Sanyal AJ，Mathurin P，Nagy LA. Commonalities and distinctions between alcoholic and nonalcoholic fatty liver disease. Gastroenterology，2016，150（8）:1695-1697.
[23] Hong SH，Lee JM，Choi JH，et al. Perioperative assessment of terlipressin infusion during living donor liver transplantation. J Int Med Res，2012，40（1）:225-236.
[24] 李民，熊俊. 特利加压素控制肝癌肝切除术后腹腔积液形成的前瞻性研究. 中华消化外科杂志，2012，11（6）:518-521.
[25] Fahrner R，Patsenker E，De GA，et al. Elevated liver regeneration in response to pharmacological reduction of elevated portal venous pressure by terlipressin after partial hepatectomy. Transplantation，2014，97（9）:892-900.

Therapeutic effects of terlipressin in treatment of patients with decompensated cirrhosis resulting from chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

Comments

[1]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[2]	Xu Manman, Chen Yu, Li shuang. Predictive value of urinary NGAL and KIM-1 for response of patients with hepatorenal syndrome to terlipressin combined with albumin infusion treatment [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 385-388.
[3]	Pang Guohong, Li Lingjun, Yang Rulei. Changes of hepatic vein pressure gradients in patients with liver cirrhosis and upper gastrointestinal bleeding receiving terlipressin combined with esomeprazole [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 364-365.
[4]	Wang Jun，Peng Hao. Observation of terlipressin and somatostatin in the treatment of patients with liver cirrhosis complicated by esophageal and gastric varices bleeding [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 418-419.
[5]	Wu Jun. Comparison of terlipressin and torsemide in the treatment of patients with decompensated cirrhosis and hepatorenal syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 78-79.